ANDA 202338, held by Rising. Imipramine Pamoate.
As of Nov 16, 2026, ANDA 202338 (Imipramine Pamoate), held by Rising, was first approved by FDA on Jun 28, 2013, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 28, 2013 | Original application | Approved | None posted |
| Imipramine PamoateEQ 75MG HYDROCHLORIDE · capsule;oral | Imipramine Pamoate | Discontinued |
| Imipramine PamoateEQ 100MG HYDROCHLORIDE · capsule;oral | Imipramine Pamoate | Discontinued |
| Imipramine PamoateEQ 125MG HYDROCHLORIDE · capsule;oral | Imipramine Pamoate | Discontinued |
| Imipramine PamoateEQ 150MG HYDROCHLORIDE · capsule;oral | Imipramine Pamoate | Discontinued |
| Jun 24, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 27, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 28, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters